Skip to content

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

News

Select Year
Clinical Trials
Search …

November 9, 2023

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

November 9, 2023

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

November 3, 2023

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

November 3, 2023

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights

October 23, 2023

Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO

October 23, 2023

Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study

October 20, 2023

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

October 16, 2023

Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023

September 26, 2023

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

September 19, 2023

Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference

Page 10 of 71

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

Our Mission
Leadership
Board of Directors
Careers
Contact

Science

Our Science
Pipeline
Resources

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent

Copyright © 2026 Oncolytics Biotech Inc.